Osteoanabolic therapy for osteoporosis in women

References

• Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595–1622.
   PubMed Web of Science ®Google Scholar
• Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract. 2020;26(Suppl 1):1–46.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020;31(1):1–12.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285(3):320–323.
   PubMed Web of Science ®Google Scholar
• van Geel TA, van Helden S, Geusens PP, et al. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2009;68(1):99–102.
   PubMed Web of Science ®Google Scholar
• Bynum JPW, Bell JE, Cantu RV, et al. Second fractures among older adults in the year following hip, shoulder, or wrist fracture. Osteoporos Int. 2016;27(7):2207–2215.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Odén A, et al. Characteristics of recurrent fractures. Osteoporos Int. 2018;29(8):1747–1757.
   PubMed Web of Science ®Google Scholar
• Balasubramanian A, Zhang J, Chen L, et al. Risk of subsequent fracture after prior fracture among older women. Osteoporos Int. 2019;30(1):79–92.
   PubMed Web of Science ®Google Scholar
• Adachi JD, Brown JP, Schemitsch E, et al. Fragility fracture identifies patients at imminent risk for subsequent fracture: real-world retrospective database study in Ontario, Canada. BMC Musculoskelet Disord. 2021;22(1):224.
   PubMed Web of Science ®Google Scholar
• Kendler DL, Bauer DC, Davison KS, et al. Vertebral fractures: clinical importance and management. Am J Med. 2016;129(2):221.e1–10.
   Web of Science ®Google Scholar
• Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab. 2020;105(3):587–594.
   Web of Science ®Google Scholar
• NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785–795.
   PubMed Web of Science ®Google Scholar
• Minisola S, Cipriani C, Grotta GD, et al. Update on the safety and efficacy of teriparatide in the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2019;11:1759720X19877994.
   PubMed Web of Science ®Google Scholar
• Miller PD, Bilezikian JP, Fitzpatrick LA, et al. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. Curr Med Res Opin. 2020;36(11):1861–1872.
   PubMed Web of Science ®Google Scholar
• Arlot M, Meunier PJ, Boivin G, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res. 2005;20(7):1244–1253.
   PubMed Web of Science ®Google Scholar
• Dempster DW, Zhou H, Rao SD, et al. Early effects of abaloparatide on bone formation and resorption indices in postmenopausal women with osteoporosis. J Bone Miner Res. 2021;36(4):644–653.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Matsumoto T. Sclerostin: from bench to bedside. J Bone Miner Metab. 2021;39(3):332–340.
   PubMed Web of Science ®Google Scholar
• Chavassieux P, Chapurlat R, Portero-Muzy N, et al. Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment. J Bone Miner Res. 2019;34(9):1597–1608.
   PubMed Web of Science ®Google Scholar
• Cosman F, Dempster DW. Anabolic agents for postmenopausal osteoporosis: how do you choose? Curr Osteoporos Rep. 2021;19(2):189–205.
   PubMed Web of Science ®Google Scholar
• Liu Y, Cao Y, Zhang S, et al. Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials. Climacteric. 2018;21(2):189–195.
   PubMed Web of Science ®Google Scholar
• McClung MR. Role of bone-forming agents in the management of osteoporosis. Aging Clin Exp Res. 2021;33(4):775–791.
   PubMed Web of Science ®Google Scholar
• Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis. JAMA. 2016;316(7):722–733.
   PubMed Web of Science ®Google Scholar
• Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–1543.
   PubMed Web of Science ®Google Scholar
• Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–1427.
   PubMed Web of Science ®Google Scholar
• McClung MR, Brown JP, Diez-Perez A, et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res. 2018;33(8):1397–1406.
   PubMed Web of Science ®Google Scholar
• Adami S, San Martin J, Munoz-Torres M, et al. Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int. 2008;19(1):87–94.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, et al. One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME Extension study. J Bone Miner Res. 2019;34(3):419–428.
   PubMed Web of Science ®Google Scholar
• Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015;386(9999):1147–1155.
   PubMed Web of Science ®Google Scholar
• Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189–1199.
   PubMed Web of Science ®Google Scholar
• Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–523.
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441.
   PubMed Web of Science ®Google Scholar
• Díez-Pérez A, Marin F, Eriksen EF, et al. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis. Bone. 2019;120:1–8.
   PubMed Web of Science ®Google Scholar
• Bone HG, Cosman F, Miller PD, et al. ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab. 2018;103(8):2949–2957.
   PubMed Web of Science ®Google Scholar
• Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391(10117):230–240.
   PubMed Web of Science ®Google Scholar
• Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028–2039.
   PubMed Web of Science ®Google Scholar
• Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390(10102):1585–1594.
   PubMed Web of Science ®Google Scholar
• McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–420.
   PubMed Web of Science ®Google Scholar
• Genant HK, Engelke K, Bolognese MA, et al. Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res. 2017;32(1):181–187.
   PubMed Web of Science ®Google Scholar
• Keaveny TM, Crittenden DB, Bolognese MA, et al. Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass. J Bone Miner Res. 2017;32(9):1956–1962.
   PubMed Web of Science ®Google Scholar
• Reeve J, Bradbeer JN, Arlot M, et al. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses. Osteoporos Int. 1991;1(3):162–170.
   PubMedGoogle Scholar
• Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997;350(9077):550–555.
   PubMed Web of Science ®Google Scholar
• Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest. 1998;102(8):1627–1633.
   PubMed Web of Science ®Google Scholar
• Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab. 2000;85(2):720–726.
   PubMed Web of Science ®Google Scholar
• Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3):503–511.
   PubMed Web of Science ®Google Scholar
• Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res. 2005;20(11):1905–1911.
   PubMed Web of Science ®Google Scholar
• Leder BZ, Tsai JN, Uihlein AV, et al. Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA Extension study): a randomized controlled trial. J Clin Endocrinol Metab. 2014;99(5):1694–1700.
   PubMed Web of Science ®Google Scholar
• Palacios S, Mejía A. Antiresorptives and anabolic therapy in sequence or combination for postmenopausal osteoporosis. Climacteric. 2015;18(4):453–455.
   PubMed Web of Science ®Google Scholar
• Vahle JL, Long GG, Sandusky G, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol. 2004;32(4):426–438.
   PubMed Web of Science ®Google Scholar
• Jolette J, Attalla B, Varela A, et al. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34). Regul Toxicol Pharmacol. 2017;86:356–365.
   PubMed Web of Science ®Google Scholar
• Gilsenan A, Midkiff K, Harris D, et al. Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study. J Bone Miner Res. 2021;36(2):244–251.
   PubMed Web of Science ®Google Scholar
• Amgen I. Bone, Reproductive and Urologic Drugs Advisory Committee for Romosozumab Briefing Materials; 2019. Available from: https://www.fda.gov/media/121255/download.
   Google Scholar
• Turk JR, Deaton AM, Yin J, et al. Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture. Regul Toxicol Pharmacol. 2020;115:104697.
   PubMed Web of Science ®Google Scholar
• Cummings SR, McCulloch C. Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab. Osteoporos Int. 2020;31(6):1019–1021.
   PubMed Web of Science ®Google Scholar
• Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25(2):404–414.
   PubMed Web of Science ®Google Scholar
• Bhandari M, Schemitsch EH, Karachalios T, et al. Romosozumab in skeletally mature adults with a fresh unilateral tibial diaphyseal fracture: a randomized phase-2 study. J Bone Joint Surg Am. 2020;102(16):1416–1426.
   PubMed Web of Science ®Google Scholar
• Schemitsch EH, Miclau T, Karachalios T, et al. A randomized, placebo-controlled study of romosozumab for the treatment of hip fractures. J Bone Joint Surg Am. 2020;102(8):693–702.
   PubMed Web of Science ®Google Scholar
• Conradie M, de Villiers T. Premenopausal osteoporosis. Climacteric. 2021;24:1–14.
   PubMedGoogle Scholar
• Nishiyama KK, Cohen A, Young P, et al. Teriparatide increases strength of the peripheral skeleton in premenopausal women with idiopathic osteoporosis: a pilot HR-pQCT study. J Clin Endocrinol Metab. 2014;99(7):2418–2425.
   PubMed Web of Science ®Google Scholar
• Cohen A, Shiau S, Nair N, et al. Effect of teriparatide on bone remodeling and density in premenopausal idiopathic osteoporosis: a phase II trial. J Clin Endocrinol Metab. 2020;105(10):dgaa489.
   PubMed Web of Science ®Google Scholar
• Hardcastle SA. Pregnancy and lactation associated osteoporosis. Calcif Tissue Int. 2021 Feb 23. DOI:https://doi.org/10.1007/s00223-021-00815-6.
   Google Scholar
• Hellmeyer L, Boekhoff J, Hadji P. Treatment with teriparatide in a patient with pregnancy-associated osteoporosis. Gynecol Endocrinol. 2010;26(10):725–728.
   PubMed Web of Science ®Google Scholar
• Cerit ET, Cerit M. A case of pregnancy and lactation associated osteoporosis in the third pregnancy; robust response to teriparatide despite delayed administration. Bone Rep. 2020;13:100706.
   PubMedGoogle Scholar
• Milat F, Vincent AJ. Management of bone disease in women after breast cancer. Climacteric. 2015;18(sup2):47–55.
   PubMed Web of Science ®Google Scholar
• Lee YK, Lee EG, Kim HY, et al. Osteoporotic fractures of the spine, hip, and other locations after adjuvant endocrine therapy with aromatase inhibitors in breast cancer patients: a meta-analysis. J Korean Med Sci. 2020;35(46):e403.
   PubMed Web of Science ®Google Scholar
• Wagner-Johnston ND, Sloan JA, Liu H, et al. 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: NO3CC (Alliance) trial. Cancer. 2015;121(15):2537–2543.
   PubMed Web of Science ®Google Scholar
• Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9992):433–443.
   PubMed Web of Science ®Google Scholar